Patents by Inventor Marian C. Bryan

Marian C. Bryan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11981658
    Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
    Type: Grant
    Filed: August 26, 2022
    Date of Patent: May 14, 2024
    Assignees: Yuhan Corporation, Janssen Biotech, Inc.
    Inventors: Byoungmoon Lee, Hyunjoo Lee, Gyu Jin Lee, Su Bin Choi, Sol Park, Heejun Kim, Misong Kim, Young Ae Yoon, Kwan Hoon Hyun, Tae Kyun Kim, Jae Young Sim, Marian C. Bryan, Scott Kuduk, James Campbell Robertson
  • Patent number: 11945798
    Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
    Type: Grant
    Filed: August 26, 2022
    Date of Patent: April 2, 2024
    Assignees: YUHAN CORPORATION, JANSSEN BIOTECH, INC.
    Inventors: Hyunjoo Lee, Su Bin Choi, Young Ae Yoon, Kwan Hoon Hyun, Jae Young Sim, Marian C. Bryan, Scott Kuduk, James Campbell Robertson, Jaekyoo Lee, Paresh Devidas Salgaonkar, Byung-Chul Suh, Jong Sung Koh, So Young Hwang
  • Publication number: 20230167123
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: December 8, 2022
    Publication date: June 1, 2023
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, F. Anthony Romero, Marian C. Bryan
  • Publication number: 20230086795
    Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
    Type: Application
    Filed: August 26, 2022
    Publication date: March 23, 2023
    Applicants: YUHAN CORPORATION, JANSSEN BIOTECH, INC.
    Inventors: Hyunjoo LEE, Su Bin CHOI, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell Robertson, Jaekyoo LEE, Paresh Devidas SALGAONKAR, Byung-Chul SUH, Jong Sung KOH, So Young HWANG
  • Publication number: 20230085912
    Abstract: Provided are 5-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
    Type: Application
    Filed: August 26, 2022
    Publication date: March 23, 2023
    Applicants: YUHAN CORPORATION, JANSSEN BIOTECH, INC.
    Inventors: Byoungmoon LEE, Hyunjoo LEE, Gyu Jin LEE, Su Bin CHOI, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell ROBERTSON, Jaekyoo LEE, Paresh Devidas SALGAONKAR, Byung-Chul SUH, Jong Sung KOH, So Young HWANG
  • Publication number: 20230086884
    Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
    Type: Application
    Filed: August 26, 2022
    Publication date: March 23, 2023
    Applicants: YUHAN CORPORATION, JANSSEN BIOTECH, INC.
    Inventors: Byoungmoon LEE, Hyunjoo LEE, Gyu Jin LEE, Su Bin CHOI, Sol PARK, Heejun KIM, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Tae Kyun KIM, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell ROBERTSON
  • Publication number: 20230016791
    Abstract: wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: August 24, 2022
    Publication date: January 19, 2023
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Marie Grandner, Daniel G.M. Shore, Marian C. Bryan
  • Publication number: 20220332718
    Abstract: A method for treating an inflammatory or autoimmune disease with compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Application
    Filed: February 10, 2021
    Publication date: October 20, 2022
    Applicant: Genentech, Inc.
    Inventors: Marian C. Bryan, Alberto Gobbi, James Richard Kiefer, Jr., Aleksandr Kolesnikov, Alan G. Olivero, Joy Drobnick, Jun Liang, Naomi Rajapaksa, Chudi Ndubaku, Jianwen Feng
  • Patent number: 11453671
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: September 27, 2022
    Assignee: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G. M. Shore, Marian C. Bryan
  • Patent number: 11434250
    Abstract: Compounds of Formula I and methods of use as Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: September 6, 2022
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Joy Drobnick, James Richard Kiefer, Jr., Aleksandr Kolesnikov, Naomi S. Rajapaksa
  • Publication number: 20220106322
    Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Wei Li, Daniel G.M. Shore, F. Anthony Romero, Marian C. Bryan
  • Patent number: 11034698
    Abstract: Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: June 15, 2021
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Steven Do, Joy Drobnick, Alberto Gobbi, Tamiko Katsumoto, James Richard Kiefer, Jr., Jun Liang, Naomi S. Rajapaksa, Yongsheng Chen, Liqiang Fu, Kwong Wah Lai, Zhiguo Liu, John Wai, Fei Wang
  • Patent number: 10988478
    Abstract: Compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: April 27, 2021
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Alberto Gobbi, James Richard Kiefer, Jr., Aleksandr Kolesnikov, Alan G. Olivero, Joy Drobnick, Jun Liang, Naomi Rajapaksa, Chudi Ndubaku, Jianwen Feng
  • Patent number: 10899772
    Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: January 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Steven Do, Tamiko Katsumoto, Jun Liang, Naomi S. Rajapaksa, James Richard Kiefer, Jr., Liqiang Fu
  • Patent number: 10899774
    Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: January 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Joy Drobnick, Alberto Gobbi, Tamiko Katsumoto, Naomi S. Rajapaksa, James Richard Kiefer, Jr.
  • Publication number: 20200399275
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, Marian C. Bryan
  • Publication number: 20200399274
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, F. Anthony Romero, Marian C. Bryan
  • Publication number: 20200262845
    Abstract: Compounds of Formula I and methods of use as Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitors are described herein.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 20, 2020
    Applicant: Genentech, Inc.
    Inventors: Marian C. BRYAN, Joy DROBNICK, James Richard KIEFER, JR., Aleksandr KOLESNIKOV, Naomi S. RAJAPAKSA
  • Publication number: 20200123166
    Abstract: Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 23, 2020
    Applicant: Genentech, Inc.
    Inventors: Marian C. BRYAN, Steven DO, Joy DROBNICK, Alberto GOBBI, Tamiko KATSUMOTO, James Richard KIEFER, Jr., Jun LIANG, Naomi S. RAJAPAKSA, Yongsheng CHEN, Liqiang FU, Kwong Wah LAI, Zhiguo LIU, John WAI, Fei WANG
  • Publication number: 20200115388
    Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 16, 2020
    Applicant: Genentech, Inc.
    Inventors: Marian C. BRYAN, Joy DROBNICK, Alberto GOBBI, Tamiko KATSUMOTO, Naomi S. RAJAPAKSA, James Richard KIEFER, JR.